Nebenwirkungen · Pomalidomide Teva
Pomalidomide Teva 1 mg hard capsules Pomalidomide Teva 2 mg hard capsules Pomalidomide Teva 3 mg hard capsules Pomalidomide Teva 4 mg hard capsules · Abschnitt 4.8 · PDF-Seite 21
HOS-152604 · Präparat HOS-100789
Peripheral neuropathy - Pomalidomide in combination with bortezomib and dexamethasone Patients with ongoing peripheral neuropathy ≥ Grade 2 with pain within 14 days prior to randomisation were excluded from clinical trials. Peripheral neuropathy occurred in 55.4 % of patients (10.8% Grade 3; 0.7% Grade 4). Exposure-adjusted rates were comparable across treatment arms. Approximately 30% of the patients experiencing peripheral neuropathy had a history of neuropathy at baseline. Peripheral neuropathy led to discontinuation of bortezomib in approximately 14.4% of patients, pomalidomide in 1.8% and dexamethasone in 1.8% of patients in the Pom+Btz+Dex arm and 8.9% of patients in the Btz+Dex arm.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-01T10:30:00Z · SHA-256 3ab54e22d7d43396e292fa7f180836a63e26f28dcb2f9290cf9a99a3058c6c74 · Passage e85bc18362f522664eddae2576938a324ef95abcbf7847b61da5367a05e536b8 · Zeichen 17819–18517 im Abschnitt